Abiopharma

🔍 McDermott Wendy (Executive)

Company: LEXICON PHARMACEUTICALS, INC. (LXRX)

Report Date: 2026-02-28

Detailed Transactions and Holdings:

• Acquired 27,697 shares of Common Stock (Direct)
  Date: 2026-02-28 | Code: M | equity_swap_involved: 0 | shares_owned_after: 149,343.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 52,316 shares of Common Stock (Direct)
  Date: 2026-02-28 | Code: M | equity_swap_involved: 0 | shares_owned_after: 201,659.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 144,393 shares of Common Stock (Direct)
  Date: 2026-02-28 | Code: M | equity_swap_involved: 0 | shares_owned_after: 346,052.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 68,107 shares of Common Stock at $1.47 per share (Direct)
  Date: 2026-02-28 | Code: F | equity_swap_involved: 0 | shares_owned_after: 277,945.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 27,697 shares of Restricted Stock Units (Derivative)
  Date: 2026-02-28 | Code: M | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F1, F3, F3
• Sold 52,316 shares of Restricted Stock Units (Derivative)
  Date: 2026-02-28 | Code: M | equity_swap_involved: 0 | shares_owned_after: 52,317.00 | transaction_form_type: 4 | Footnotes: F1, F1, F3, F3
• Sold 144,393 shares of Restricted Stock Units (Derivative)
  Date: 2026-02-28 | Code: M | equity_swap_involved: 0 | shares_owned_after: 288,787.00 | transaction_form_type: 4 | Footnotes: F1, F1, F3, F3

Footnotes:

• F1: Each restricted stock unit represents a contingent right to receive one share of common stock.
• F2: Withholding of a portion of issued shares by the Company in satisfaction of shareholder's tax withholding obligations with respect thereto.
• F3: Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant.